FODMAPs infused into colon: new clues for IBS?
NCT ID NCT06488534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how FODMAPs—carbohydrates that can cause bloating and gas—affect the movement of the colon and related symptoms. Fifteen healthy volunteers received FODMAPs directly into the colon during three separate visits. The goal was to measure colon pressure changes and track any abdominal symptoms, helping researchers better understand what triggers IBS.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- FODMAPs (fermentable carbohydrates)
- What this could lead to
- If successful, this could help explain how certain foods trigger IBS symptoms, potentially guiding future dietary therapies.
- What could go wrong
- This is a small, early study in healthy volunteers, not patients. Results may not apply to people with IBS or lead directly to treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
15 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects should provide written informed consent to participate in the study * Women of child-bearing potential agree to apply a highly effective method of birth control during the entire duration of the trial. Highly effective birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used constantly and correctly such as implants, injectables, combined oral contraceptive method, or some intrauterine devices (IUDs), sexual abstinence, or vasectomized partner. Women of non-childbearing potential may be included if surgically sterile (tubal ligation or hysterectomy) or postmenopausal with at least 2 years without spontaneous menses. * Subjects who are capable to understand the study and the questionnaires, and to comply with the study requirements. * Healthy volunteers should consider themselves healthy and should not be medically examined Exclusion Criteria: * History of major surgery of the gastrointestinal tract (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post-surgery are allowed). * Known underlying organic gastrointestinal disease, including intestinal obstruction, ileus, intestinal perforation, severe inflammatory disorder like ulcerative colitis, Crohn's disease or toxic megacolon * Diabetes mellitus types 1 and 2 * Concomitant Kidney or Liver disease, Biliary obstruction * Decreased cardiac -or respiratory function * Pregnant or breastfeeding women * Use of antibiotics in the past month * History of skin allergies or a history of extreme sensitivity to cosmetics or lotions * Fragile skin vulnerable to skin tears. * Damaged epigastric skin (open wounds, rash, inflammation) * Subjects who are unable to remain in a relaxed reclined position for the test duration * Subject has received an investigational drug or used an investigational medical device within 30 days prior to randomization, or is currently enrolled in an investigational study. * The use of following drugs 1 month prior to inclusion and during the whole study duration: laxatives, opioids, anti-acids, anticholinergics/antispasmodics, anticonvulsants, antidepressants, diuretics, antihypertensives, antipsychotics, calcium channel blockers, bile acid sequestrants, iron supplements, anticoagulants, HIV protease inhibitors (saquinavir, lopinavir), atorvastatine, negazodone, efavirenz, Sint-janskruid (CYP3A4 inducers)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
KU Leuven
Leuven, Vlaams-Brabant, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a website teach patients to tame gut pain and skip needless hospital tests?
- Could allergy pills calm irritable bowel syndrome?
- Can cutting certain carbs or gluten calm irritable bowel syndrome?
- Could a nickel allergy explain your Child's stomach pain?
- Ancient wisdom meets AI: could TCM features sharpen colorectal screening?
- Can cutting certain foods calm irritable bowel syndrome?